Seattle biotech startup led by Adaptive, Fred Hutch vets raises $16M for rapid drug development tech

Lumen Chief Science Officer Jim Roberts (left) and CEO Brian Finnow. (Lumen Photo)

Lumen Bioscience today announced a $16 million Series B round to help support its novel approach to rapid and low-cost drug development.

The company has come up with a way to produce orally-delivered antibodies

This post was originally published on this site


Check out